Johns Hopkins Medicine Office of Continuing Medical Education
Skip Navigation.
How ToAbout CMECME CalendarOnline/EnduringProgramsResources & DownloadsContact & Travel InformationBlog
CME Online
Forgot your password?

Not Registered yet?

Create a new account.

80023976: What's New in Diabetic Retinopathy and Venous Occlusive Disease?

November 11, 2011
  • Download Brochure
  • Send to Colleague
  • Back to List
What’s New in Diabetic Retinopathy Brochure Cover Image


Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DESCRIPTION

The total number of people worldwide with diabetes mellitus is projected to rise from 171 million in 2000 to 366 million in 2030. In the United States, almost 24 million or 8 percent of the population has diabetes mellitus. Approximately 4.0 million Americans age 40 and older have diabetic retinopathy, 900,000 of whom have vision threatening disease, defined as pre-proliferative retinopathy, macular edema, or both. Diabetic retinopathy remains the leading cause of blindness in adults who make up the work force. Despite this, diabetic retinopathy and venous occlusive disease are often under-diagnosed and under-treated. This annual course highlights new information being reported by the Diabetic Retinopathy Clinical Research Network and others, which will impact current standard care and management strategies. Outcomes data confirming the superiority of ranibizumab over traditional laser therapy in the management of diabetic macular edema will also be reviewed.

OBJECTIVES

After attending this activity, the participant will demonstrate the ability to:

  • Summarize the evidence of relation of diabetic control to incidence and severity of retinopathy
  • Diagnose diabetic macular edema, severe non-proliferative retinopathy, and high risk proliferative diabetic retinopathy
  • Determine how best to manage diabetic macular edema, severe non-proliferative diabetic retinopathy, and high risk proliferative diabetic retinopathy
  • Recognize new experimental treatment options

Hotel Information
Hyatt Regency Baltimore
300 Light Street
Baltimore, Maryland 21202
Phone: (800) 233-1235 or (510) 528-1235
Fax: (510) 605-2870
Web site: www.baltimore.hyatt.com

HOTEL RESERVATION CUT-OFF DATE: OCTOBER 20, 2011
A limited block of sleeping rooms has been reserved for your convenience and will be available on a first come, first served basis.


The Hyatt Regency Baltimore, centrally located on the Inner Harbor and an industry leader since its opening, holds the longest four-diamond award status in the state with beautiful guestrooms, Bistro 300 and a commitment to excellent service. Make your reservation online at https://resweb.passkey.com/go/JohnsHopkins or call the hotel directly and specify that you are attending the Johns Hopkins Diabetic Retinopathy Activity to receive the special group rate of $199, single or double, plus tax. Complimentary Roundtrip Transportation will be provided. On-site parking is available at an additional charge. Check-in time is 4:00 p.m. Check out time is 12:00 noon.

Talks

November 11, 2011  7:55 AM to 8:00 AM

Welcome and Introduction

Goldberg, Morton
November 11, 2011  8:00 AM to 8:05 AM

Conference Goals

Solomon, Sharon
November 11, 2011  8:05 AM to 9:15 AM

Epidemiology and Medical Management-MODERATOR

Solomon, Sharon
November 11, 2011  8:05 AM to 8:25 AM

Epidemiology of Diabetic Retinopathy and Retinal Venous Occlusive Disease

Gower, Emily
To characterize the epidemiology of diabetic retinopathy and retinal venous occlusive disease. To discuss risk factors for disease progression.
November 11, 2011  8:25 AM to 8:45 AM

The Metabolic Syndrome and the Prevention of Diabetes

Margolis, Simeon
To recognize the features and risks of the metabolic syndrome.
November 11, 2011  8:45 AM to 9:05 AM

An Ophthalmologist’s Guide to Diabetes Medical Management in 2011

Kalyani, Rita
To recognize an algorithmic approach to using oral agents and insulin in the management of type 2 diabetes mellitus. To recognize the importance of hypertension management in the prevention of renal and cardiovascular disease in diabetes. To discuss the role of aggressive cholesterol lowering in the prevention of cardiovascular disease in diabetes.
November 11, 2011  9:05 AM to 9:15 AM

Questions and Discussion

Solomon, Sharon
November 11, 2011  9:15 AM to 10:00 AM

Management of Diabetic Macular Edema-MODERATOR

Sodhi, Akrit
November 11, 2011  9:15 AM to 9:35 AM

Overview of Pharmacologic Therapies for Diabetic Macular Edema

Solomon, Sharon
To recognize various therapies available for the medical management of diabetic macular edema.
November 11, 2011  9:35 AM to 9:50 AM

Retreatment Algorithms: What To Do After Starting Anti-VEGF Therapy

Bressler, Neil
To describe the underlying principles used to develop a web-based algorithm that incorporates intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema in a Diabetic Retinopathy Clinical Research Network randomized clinical trial.
November 11, 2011  9:50 AM to 10:00 AM

Questions and Discussion

Sodhi, Akrit
November 11, 2011  10:25 AM to 10:40 AM

Sustained-Delivery Vitreous Inserts and Diabetic Macular Edema

Campochiaro, Peter
To summarize recent data regarding vitreous inserts for the treatment of DME.
November 11, 2011  10:40 AM to 10:55 AM

Is There a Role for Vitrectomy or Pharmacologic Treatment of Vitreomacular Adhesions for Diabetic Macular Edema?

Pieramici, Dante
To update on the role of vitrectomy and new agents to monitor the vitrectomy of patients with diabetic macular edema.
November 11, 2011  10:55 AM to 11:05 AM

The Role of OCT in the Management of DME

Bressler, Susan
To know the roles that OCT's play in diagnosis and management of DME; To know the normal values of central subfield thickness in persons with diabetes; To calculate what change in OCT thickness represents a real change in disease status.
November 11, 2011  11:05 AM to 11:20 AM

Is There Still a Role for Fluorescein Angiography? How About Wide-Field Imaging?

Bressler, Neil
To discuss the role of fluorescein angiography, including wide-field imaging in an era of anti-VEGF therapy for diabetic macular edema and proliferative diabetic retinopathy.
November 11, 2011  11:20 AM to 11:35 AM

ASRS PAT Survey on DME; AAO Preferred Practice Pattern on DME: Guidelines on Treatment

Thompson, John
To review consensus of use of different modalities of treatment for diabetic macular edema.
November 11, 2011  11:35 AM to 12:30 PM

Managing Diabetic Macular Edema in 2011: Case Presentations

Bressler, Neil
November 11, 2011  11:35 AM to 12:30 PM

Managing Diabetic Macular Edema in 2011: Case Presentations

Campochiaro, Peter
November 11, 2011  11:35 AM to 12:30 PM

Managing Diabetic Macular Edema in 2011: Case Presentations

Pieramici, Dante
To review the latest treatments and management of diabetic macular edema.
November 11, 2011  11:35 AM to 12:30 PM

Managing Diabetic Macular Edema in 2011: Case Presentations

Thompson, John
November 11, 2011  11:35 AM to 12:30 PM

Managing Diabetic Macular Edema in 2011: Case Presentations-MODERATOR

Solomon, Sharon
November 11, 2011  1:30 PM to 1:45 PM

Impact of Intravitreal Corticosteroids or Anti-VEGF Drugs on Progression/Regression of Diabetic Retinopathy?

Zimmer-Galler, Ingrid
To recognize the role of intravitreal agents on the progression of diabetic retinopathy.
November 11, 2011  1:30 PM to 2:30 PM

Management of Proliferative Diabetic Retinopathy-MODERATOR

Gehlbach, Peter
November 11, 2011  1:45 PM to 2:00 PM

Proliferative Diabetic Retinopathy: PRP or Anti-VEGF Agents or Both?

Scott, Adrienne
To discuss the current evidence for the use of panretinal photocoagulation and/or anti-VEGF agents in the treatment of proliferative diabetic retinopathy.
November 11, 2011  2:00 PM to 2:10 PM

Vitrectomy for Proliferative Diabetic Retinopathy

Gehlbach, Peter
To discuss the presented research topic.
November 11, 2011  2:10 PM to 2:30 PM

Surgical Case Presentations

Pieramici, Dante
To review latest surgical treatments in the management of diabetic macular edema.
November 11, 2011  2:10 PM to 2:30 PM

Surgical Case Presentations

Scott, Adrienne
To discuss the most advantageous surgical strategies in the treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage and/or traction retinal detachment.
November 11, 2011  2:10 PM to 2:30 PM

Surgical Case Presentations

Scholl, Hendrik
November 11, 2011  2:10 PM to 2:30 PM

Surgical Case Presentations

Thompson, John
November 11, 2011  2:10 PM to 2:30 PM

Surgical Case Presentations

Zimmer-Galler, Ingrid
November 11, 2011  2:10 PM to 2:30 PM

Surgical Case Presentations-MODERATOR

Gehlbach, Peter
November 11, 2011  2:30 PM to 5:00 PM

Management of Retinal Vein Occlusions-MODERATOR

Scott, Adrienne
November 11, 2011  2:30 PM to 2:45 PM

Why Isn’t a Medical Work-up Indicated for Venous Occlusive Disease?

Finkelstein, Daniel
To recognize the evaluation of appropriate testing for vein occlusion systemic associations.
November 11, 2011  2:45 PM to 3:05 PM

Anti-VEGF Drugs or Corticosteroids for Macular Edema from Retinal Vein Occlusion?

Ying, Howard
To make evidence-based decisions for the appropriate use of anti-VEGF drugs or corticosteroids for macular edema from retinal vein occlusion.
November 11, 2011  3:30 PM to 3:45 PM

Management of Capillary Non-perfusion and Neovascularization following Retinal Vein Occlusion

Sodhi, Akrit
To learn about the pathophysiology, clinical consequences and treatment options for capillary non-perfusion and neovascularization following retinal vein occlusion.
November 11, 2011  3:45 PM to 4:45 PM

Managing Retinal Vein Occlusions

Bressler, Susan
November 11, 2011  3:45 PM to 4:45 PM

Managing Retinal Vein Occlusions

Finkelstein, Daniel
To discuss rationale for considering, with the patient, advisability for laser or withholding laser for BVO or CVO.
November 11, 2011  3:45 PM to 4:45 PM

Managing Retinal Vein Occlusions

Pieramici, Dante
To review latest treatment in retinal vein occlusions.
November 11, 2011  3:45 PM to 4:45 PM

Managing Retinal Vein Occlusions

Scott, Adrienne
To compare and contrast the various treatment modalities in the management of retinal vein occlusions.
November 11, 2011  3:45 PM to 4:45 PM

Managing Retinal Vein Occlusions

Scholl, Hendrik
November 11, 2011  3:45 PM to 4:45 PM

Managing Retinal Vein Occlusions

Ying, Howard
To manage cases of retinal vein occlusions.
November 11, 2011  3:45 PM to 4:45 PM

Managing Retinal Vein Occlusions-MODERATOR

Sodhi, Akrit
November 11, 2011  4:45 PM to 5:00 PM

Final Questions and Answers/Closing Remarks

Solomon, Sharon

Policy On Speaker And Provider Disclosure

It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.

Event Information
Johns Hopkins School of Medicine, Turner Auditorium
720 Rutland Ave
Baltimore, MD
Directions

Target Audience(s)

This activity is intended for Ophthalmologists, Retina Specialists, Residents, Fellows and other Health Care Professionals.

Course Director

Sharon Solomon

Course Co-Director

Neil Bressler

Lodging

Hyatt Regency Baltimore
300 Light Street
Baltimore, Maryland 21202
Phone: (800) 233-1234 or (510) 528-1234
Fax: (510) 605-2870

Hotel Website

www.baltimore.hyatt.com
HOTEL RESERVATION CUT-OFF DATE:
OCTOBER 20, 2011

Contact Info

General Info: 410.502.9634

Mailing Address:
Johns Hopkins University School
of Medicine
Thomas B. Turner Building
720 Rutland Avenue, Room 20
Baltimore, Maryland 21205-2195

Email Us

© 2012 Johns Hopkins University
School of Medicine | Office of Continuing Medical Education
Home | Privacy Policy | Sitemap
Managed Hosting by PEER 1
HTML to PDF conversion by ABCpdf.NET